Inventiva S.A. (IVA)
| Market Cap | 153.37M |
| Revenue (ttm) | 18.81M |
| Net Income (ttm) | -54.27M |
| Shares Out | 42.13M |
| EPS (ttm) | -1.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,588 |
| Open | 3.47 |
| Previous Close | 3.47 |
| Day's Range | 3.47 - 3.76 |
| 52-Week Range | 3.40 - 12.15 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 18.57 (+410.17%) |
| Earnings Date | Mar 29, 2023 |
About IVA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. Th... [Read more]
Financial Performance
In 2022, Inventiva's revenue was $18.81 million, an increase of 121.32% compared to the previous year's $8.50 million. Losses were -$54.27 million, 9.35% more than in 2021.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for IVA stock is "Buy." The 12-month stock price forecast is $18.57, which is an increase of 410.17% from the latest price.
News
Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F
Daix (France), Long Island City (New York, United States) , March 30, 2023 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral sma...
Inventiva reports its 2022 full-year results
Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results
Daix (France), Long Island City (New York, United States) , March 23 , 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the deve...
Correction: Inventiva reports preliminary financial results for Full-Year 2022¹
Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev...
Inventiva reports preliminary financial results for Full-Year 2022¹
Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev...
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
Daix (France), Long Island City (New York , United States), January 30 , 2 02 3 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...
Results of the votes of the Combined Shareholders' General Meeting of January 25, 2023
Daix (France), Long Island City (New York, United States), January 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral ...
Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis
Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to t...
Combined General Meeting of January 25, 2023 - Availability of the preparatory documents
Daix (France), Long Island City (New York, United States), January 3, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s...
Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank
Daix (France) , Long Island City (New York, United States), December 12 , 2 022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...
Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US
Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the de...
Inventiva announces a new Director of the Board of Directors
Daix (France), Long Island City (New York, United States), November 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
Inventiva reports 2022 Third Quarter Financial Information¹
Daix (France), Long Island City (New York, United States), November 10, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev...
Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022
Daix (France), Long Island City (New York, United States), October 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral ...
Inventiva reports its 2022 first-half financial results and provides a corporate update
Daix (France), Long Island City (New York, United States), September 22, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the de...
Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and commercialization of lanifibranor in Greater China
Here's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 Weeks
Inventiva S.A. Sponsored ADR (IVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results
Daix (France), Long Island City (New York, United States), September 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev...
Inventiva Reports 2022 First-Half Financial Information¹
Daix (France), Long Island City (New York, United States), July 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the develop...
Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D
Daix (France), Long Island City (New York, United States), July 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...
Update on Inventiva's cash position and on the finance documentation with the European Investment Bank
Daix (France), Long Island City (New York, United States), July 4, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developm...
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
Daix (France), Long Island City (New York, United States), June 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral sma...
Here's Why Inventiva S.A. Sponsored ADR (IVA) Could be Great Choice for a Bottom Fisher
Inventiva S.A. Sponsored ADR (IVA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
Daix (France), Long Island City (New York, United States), June 9, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...
Inventiva joins the Euronext Tech Leaders segment
Daix (France), Long Island City (New York, United States), June 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developm...